Progenics Pharmaceuticals Inc.

Mark F. Dalton has been the President and a director of Tudor Investment Corporation, an investment advisory company, and its affiliates since 1988, and has been the President and Vice Chairman of such companies since 2005. From 1979 to 1988, he served in various senior management positions at Kidder, Peabody & Co. Incorporated, including Chief Financial Officer. Mr. Dalton is currently a director of several private companies. Mr. Dalton received a B.A. from Denison University and a J.D. from Vanderbilt University Law School.

Robert J. Israel, M.D. joined us as Vice President, Medical Affairs in October 1994 and was promoted to Senior Vice President, Medical Affairs in 2002. From 1991 to 1994, Dr. Israel was Director, Clinical Research-Oncology and Immunohematology at Sandoz Pharmaceuticals Corporation. From 1988 to 1991, he was Associate Director, Oncology Clinical Research at Schering-Plough Corporation. Dr. Israel is a licensed physician and is board certified in both internal medicine and medical oncology. He received a B.A. in physics from Rutgers University and an M.D. from the University of Pennsylvania and completed an oncology fellowship at Sloan-Kettering. Dr. Israel has been a consultant to the Solid Tumor Service at Sloan-Kettering.

Alton B. Kremer, M.D., Ph.D. joined us in October 2004 as Vice President, Clinical Research. From 2000 until joining us in 2004, Dr. Kremer served as Executive Medical Director and directed opioid clinical research programs at Purdue Pharma. From 1994 to 2000, Dr. Kremer was at Janssen Pharmaceutica of the Johnson & Johnson family of companies, where he held several positions, the most recent of which was Senior Director, Clinical Research. Previously, Dr. Kremer held positions with Applied Immune Sciences and G.D. Searle & Co. He earned his M.D. and Ph.D. in Biochemistry at Case Western Reserve University and holds a B.A. degree in Biology and Chemistry from Wesleyan University.

Richard W. Krawiec, Ph.D. joined us in February 2001 as Vice President, Investor Relations and Corporate Communications and became Vice President, Corporate Affairs in February 2006. Prior to joining Progenics, Dr. Krawiec served as Vice President of Investor Relations and Corporate Communications of Cytogen Corporation from 2000 to 2001. Prior to Cytogen, Dr. Krawiec headed these departments at La Jolla Pharmaceuticals, Inc. during 1999, at Amylin Pharmaceuticals, Inc. from 1993 to 1998 and IDEC Pharmaceuticals, Inc. previously thereto. Previously, Dr. Krawiec was the founder and Editor-In-Chief of Biotechnology Week magazine and the Managing Editor and founder of Biotechnology Newswatch. Dr. Krawiec received a B.S. in Biology from Boston University and a Ph.D. in Biological Sciences from the University of Rhode Island.

Mr. Capone joined Trimeris in 2002, bringing 16 years of US and international commercial experience. Mr. Capone's previous leadership includes Vice President Marketing and Commercial Development at Triangle Pharmaceuticals, Inc. where his primary responsibility was for the commercial development of HIV, hepatitis B and cancer drug candidates. Previous to his experience at Triangle Pharmaceuticals, Mr. Capone served as the Director, Infectious Diseases and Immunology at Bristol Myers-Squibb where he led the international franchise of Antimicrobial, Antiviral, and Immunological drugs. Mr. Capone also held marketing and sales management positions in the US and the Netherlands for Lederle Pharmaceuticals, now part of Wyeth, Inc. Mr. Capone holds a BA in International Relations from Brown University and an MBA from Columbia University.

Dr. Scheinberg is Chief of the Leukemia Service at Memorial Hospital and Member and Head of the Hematopoietic Cancer Immunochemistry Laboratory at Sloan-Kettering Institute. His work is focused on the discovery of new cancer immunotherapies, such as monoclonal antibodies and vaccines, and the testing of them in clinical trials in patients with cancer. Dr. Scheinberg holds an appointment as Chairman of the Department of Molecular Pharmacology and Therapeutics and as an Attending Physician in Department of Medicine at Cornell Medical College and is an advisor to several charitable foundations and companies developing new strategies for treatment of patients with cancer. He is a former Scholar of the Lucille P. Markey Charitable Trust and a translational investigator of the Leukemia Society of America. Dr. Scheinberg trained at the New York Hospital/Cornell University Medical Center in internal medicine and at Memorial Sloan-Kettering Cancer Center in medical oncology, before joining the staff at Sloan-Kettering in 1987. He received his M.D. and Ph.D. in pharmacology and experimental therapeutics from Johns Hopkins Medical School in 1983.

Kurt W. Briner is the former President and Chief Executive Officer of Sanofi Pharma S.A. in Paris, France, a position he held from 1988 until his retirement in 2000, and he has nearly 32 years' experience in the pharmaceutical industry. Mr. Briner is currently also a director of Novo Nordisk Danmark and Galenica S.A., each a European-based pharmaceutical company. He attended Humanistisches Gymnasium in Basel and Ecole de Commerce in Basel and Lausanne.